CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse
Abstract
Immunoreactive corticotropin-releasing hormone (CRH) and somatostatin (SRIF) were measured in the cerebrospinal fluid (CSF) of 24 female in-patients, suffering from DSM-III-R major depression, both before and after antidepressant treatment. In the total group there were no significant differences between pre- and post-treatment CSF-CRH and SRIF concentrations despite satisfactory clinical improvement in each patient. However, there was a significant post-treatment reduction of the CSF-CRH concentration in the 15 patients who remained depression-free for at least 6 months following treatment, in contrast to the tendency for elevation in those 9 subjects who relapsed within 6 months. CSF-SRIF showed no similar pattern. High, or even increasing, CSF-CRH concentration during antidepressant treatment may indicate lack of normalization of an underlying process in major depression despite symptomatic improvement and predicted early relapse.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Elevated CSF levels of CRF after antidepressant treatment are associated with greater risk of relapse.
“Further evidence for the clinical relevance of the increase in HPA activity is the finding that elevated CSF levels of CRF after antidepressant treatment is associated with greater risk of relapse.56”
From Early life adversity and the epigenetic programming of hypothalamic-pituitary-adrenal function (2014) · cites this paper as [56]
Cited by
Sorted by citations
The Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532 · see citing works
Self-citationThe role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378 · see citing works
Self-citationAlder, J., Fink, N., Bitzer, J., Hösli, I., & Holzgreve, W. (2007) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701209560 · Cited by 872 · see citing works
Neurobiological similarities in depression and drug dependence: a self-medication hypothesis
Markou, A. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00113-9 · Cited by 767 · see citing works
Sex differences in stress-related psychiatric disorders: neurobiological perspectives
Bangasser, D. A., & Valentino, R. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.03.008 · Cited by 737 · see citing works
PSYCHONEUROENDOCRINOLOGY OF DEPRESSION
Plotsky, P. M., Owens, M. J., & Nemeroff, C. B. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70006-x · Cited by 672 · see citing works
Self-citationLee, Y., & Davis, M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-16-06434.1997 · Cited by 457 · see citing works
Prospective biomarkers of major depressive disorder: A systematic review and meta-analysis
Kennis, M., Gerritsen, L., van Dalen, M., Williams, A., Cuijpers, P., & Bockting, C. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0585-z · Cited by 435 · see citing works
Hypercortisolemia and depression
Gillespie, C. F., & Nemeroff, C. B. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000163456.22154.d2 · Cited by 361 · see citing works
Self-citationHayley, S., Poulter, M. O., Merali, Z., & Anisman, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.051 · Cited by 324 · see citing works
Early life adversity and the epigenetic programming of hypothalamic-pituitary-adrenal function
Anacker, C., O'Donnell, K. J., & Meaney, M. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/canacker · Cited by 237 · see citing works
Carpenter, L. L., Tyrka, A. R., McDougle, C. J., Malison, R. T., Owens, M. J., Nemeroff, C. B., & Price, L. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300375 · Cited by 209 · see citing works
Self-citationGrippo, A. J., Cushing, B. S., & Carter, C. S. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31802f054b · Cited by 196 · see citing works
Metabolic syndrome and major depressive disorder: Co-occurrence and pathophysiologic overlap
McIntyre, R. S., Rasgon, N. L., Kemp, D. E., Nguyen, H. T., Law, C. W. Y., Taylor, V. H., Woldeyohannes, H. O., Alsuwaidan, M. T., Soczynska, J. K., Kim, B., et al. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0010-0 · Cited by 127 · see citing works
Evidence for the role of corticotropin-releasing factor in major depressive disorder
Waters, R. P., Rivalan, M., Bangasser, D. A., Deussing, J. M., Ising, M., Wood, S. K., Holsboer, F., & Summers, C. H. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.011 · Cited by 93 · see citing works
Interaction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour
Beurel, E., & Nemeroff, C. B. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_306 · Cited by 64 · see citing works
Self-citationMonfrim, X., Gazal, M., De Leon, P. B., Quevedo, L., Souza, L. D., Jansen, K., Oses, J. P., Pinheiro, R. T., Silva, R. A., Lara, D. R., et al. (2014) · Bipolar Disorders · doi:10.1111/bdi.12214 · Cited by 52 · see citing works
Aubry, J.-M. (2013) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2013.09.003 · Cited by 40 · see citing works
CRHR1 Antagonists as Novel Treatment Strategies
Holsboer, F. (2001) · CNS Spectrums · doi:10.1017/s1092852900002133 · Cited by 30 · see citing works
- Authors
- Banki, C. M., Karmacsi, L., Bissette, G., & Nemeroff, C. B.
- Affiliations
- Duke Medical Center (US)
- Emory University (US)
- ORCID
- Nemeroff, Charles B.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 1992-06
- Volume
- 2
- Issue
- 2
- Pages
- 107-113
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2013323759
- Cited by
- 149
- References
- 0
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 8 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 7 · 2014: 7 · 2013: 4 · 2012: 4
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, somatostatin, cerebrospinal fluid, major depressive disorder, antidepressant response, recurrence prediction, female patients, hypothalamic-pituitary-adrenal axis
- MeSH terms
- Adult, Aged, Antidepressive Agents, Corticotropin-Releasing Hormone, Depressive Disorder, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Somatostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
